People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $527.4M | $2.4B | 2018 |
| Rain Therapeutics Inc. | — | Biotechnology | Series C | $92.0M | $2.8B | 2020 |
| Plexium, Inc. | — | Biotechnology | Series C | $60.1M | $361.5M | 2025 |
Gorjan Hrustanovic at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gorjan Hrustanovic on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| LEON CHEN | 1 | 15 |
| Michael Martin | 1 | 11 |
| Michael Grey | 1 | 10 |
| Frank McCormick | 1 | 7 |
| Franklin Berger | 1 | 7 |
| Rob Hopfner | 1 | 6 |
| Ian Clark | 1 | 5 |
| Aaron Davis | 1 | 3 |
| Marina Bozilenko | 1 | 3 |
| Cynthia Butitta | 1 | 3 |
| Cyrus Harmon | 1 | 2 |
| Lawrence Fritz | 1 | 2 |
| Peter Radovich | 1 | 2 |
| Graham Walmsley | 1 | 2 |
| Andrei Manoliu | 1 | 2 |
| Andrew Rappaport | 1 | 2 |
| Sean Bohen | 1 | 2 |
| David Myles | 1 | 2 |
| Stephen Mullennix | 1 | 1 |
| Patrick Rivers | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.